References
- Gram J, Jespersen J, Kluft C, Rijken D C. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarc-tion. Acta Med Scand 1987; 221: 149–53
- Kostis J B, Baughman J D, Kuo P T. Association of recurrent myocardial infarction with hemostatic factors. Chest 1981; 81: 571–75
- Hamsten A, Walldius G, Szamosi A, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3–9
- Meade T W, Brozovic M, Chakrabarti R R, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533–7
- Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501–5
- Holm B, Godal H C. Quantitation of the three normally occurring plasma fibrinogens in health and during socalled ‘acute phase’ by SDS electrophoresis of fibrin obtained from EDTA-plasma. Thrombosis Res 1984; 35: 279–90
- Holm B, Brosstad F, Kierulf P, Godal H C. Polymerization properties of two normally circulating fibrinogens, HMW and LMW. Evidence that the COOH-terminal end of the a-chain is of importance for fibrin polymerization. Thrombosis Res 1985; 39: 595–606
- Thorsen L I, Holm B, Brosstad F, Solum N O. Interactions of human blood platelets with three circulating plasma fibrinogens of different molecular weights. Thrombosis Res 1987; 47: 683–92
- Jepersen J, Sidelmann J. A study of the conditions and accuracy of the thrombin time assay of plasma fibrinogen. Acta Haematol 1982; 67: 2–7
- Hoegee-de Nobel E, Voskuilen M, Briet E, Brommer E JP, Nieuwenhuizen W. A monoclonal antibody-based quantitative enzyme immunoassay for the determination of plasma fibrinogen concentrations. Thromb Haemostas 1988; 60: 415–8
- Holm B, Nilsen D WT, Godal H C. Half life and incorporation into venous thrombi of the normally occurring plasma fibrinogen fractions HMW and LMW. Thrombosis Res 1986; 41: 57–66